Abstract: The present disclosure relates to compounds that modulate (i.e., regulate) proteasome activity, pharmaceutical compositions containing such compounds, and uses of these compounds and compositions for the treatment of muscle wasting. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed herein, are peptides capable of activating proteasome activity, and pharmaceutical compositions containing the peptides and methods treating Alzheimer's disease. Disclosed herein are compositions comprising: A) a peptide, wherein the peptide comprises the amino acid sequence GRKKR-RQ-AibG-RPS (SEQ ID NO: 4), or a fragment or variant thereof, B) a peptide, wherein the peptide comprises the amino acid sequence GRKKRRQ-AibG-QR-RKKRG (SEQ ID NO: 5), or a fragment or variant thereof, or C) a peptide, wherein the peptide comprises the amino acid sequence KKK/KKK-DABA-K KK (SEQ ID NO: 6) or a fragment or variant thereof.

Abstract: Described herein are compositions and methods for predicting drug responsiveness in cellular samples from cancer subjects. Described herein are compositions and methods that can help determine treatment options and select subjects for clinical trials.

Abstract: The present disclosure relates to chemical compounds that modulate proteasome activity, pharmaceutical compositions containing such compounds, and use of these compounds and compositions for the treatment of disorders of uncontrolled cellular proliferation such as, for example, a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided herein are methods of preventing or treating cancer metastasis by administering an allosteric ligand of proteasomes. Further provided are methods of monitoring the efficacy of treatment with an allosteric ligand for reducing metastatic potential of a tumor.

Abstract: The present disclosure relates to chemical compounds that modulate proteasome activity, pharmaceutical compositions containing such compounds, and use of these compounds and compositions for the treatment of disorders of uncontrolled cellular proliferation such as, for example, a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided herein are methods of preventing or treating cancer metastasis by administering an allosteric ligand of proteasomes. Further provided are methods of monitoring the efficacy of treatment with an allosteric ligand for reducing metastatic potential of a tumor.

Abstract: The present invention relates generally to novel allosteric regulators of proteasome activity, methods for preparation and use, and pharmaceutical compositions thereof. Specifically piperidine-2-carboxylic acid derivatives containing 1-oxo-aroyl group and a lipophilic ester side chain are disclosed as allosteric inhibitors of proteasome 2S activity, and as therapeutic agents for the treatment of proteasome-associated disorders in a subject.

Abstract: The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.

Abstract: The present invention relates generally to novel allosteric regulators of proteasome activity, methods for preparation and use, and pharmaceutical compositions thereof. Specifically piperidine-2-carboxylic acid derivatives containing 1-oxo-aroyl group and a lipophilic ester side chain are disclosed as allosteric inhibitors of proteasome 2S activity, and as therapeutic agents for the treatment of proteasome-associated disorders in a subject.

Abstract: The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.

Abstract: A method of analyzing circulating tumor cells includes separating circulating tumor cells from a subject's blood sample by filtration; separating CD45-negative cells from any retained blood cells; and determining the EMT-related gene expression profiles, nanomechanical and/or nanochemical properties of the collected CD45-negative CTC cells. Analysis of the collected circulating tumor cells enables the investigators to make a quick and accurate assessment of the metastatic behavior of the subject's circulating tumor cells for early castration-resistance and metastasis prediction in a clinical setting.